Hengrui subsidiary gets approval for heart failure drug trial
Shandong Shengdi Pharmaceutical, a subsidiary of Jiangsu Hengrui Medicine, received approval from the National Medical Products Administration for clinical trials of HRS-1893 tablets on April 30, 2025.
The drug is a highly selective small molecule inhibitor of cardiac myosin for treating heart failure with preserved ejection fraction. Hengrui invested approximately RMB 60.67 million in research and development for HRS-1893.
The company noted no similar drugs are currently approved globally for this indication.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime